Indoco Remedies Ltd
Indoco Remedies Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
2 of 5 strong
The short version
Overall sales are expected to achieve a 12% to 15% CAGR over the next few years due to investments in product basket and customer growth. Expect a 12%-15% sales CAGR over the next few years driven by investments in product basket and customer growth. - Operating margins are anticipated to consistently improve quarter-on-quarter, supported by better plant efficiencies and cost controls. - India and emerging market businesses are highly profitable and expected to contribute steadily to operating profit growth. - European business profitability is set to improve as manufacturing efficiencies and product mix optimize. - U.S.
From Indoco Remedies Ltd's Q1 FY27 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Overall sales are expected to achieve a 12% to 15% CAGR over the next few years due to investments in product basket and customer growth.
- API sales from the ORIC facility are expected to improve starting Q4 of the current year.
- Domestic business growth is anticipated to be high single-digit to double-digit annually, driven by top 10 brands.
- International business, especially Europe, is sizable and expected to improve profitability and growth.
- U.S. business is in a high-growth phase with profitable gross contribution, projected to increase sales steadily.
- Emerging markets show steady double-digit secondary growth, expected to rebound after minor disruptions.
2 more points from Indoco Remedies Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Indoco Remedies Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- For FY27, Indoco Remedies expects only maintenance capex, totaling less than INR 40-50 crores for the entire year.
- There are no plans for major expansion capex this year; the focus is on trimming excessive costs and improving plant efficiency.
- The company continues to invest in operational efficiencies like automation and optimizing batch sizes, but no large new capex projects are mentioned.
- There may be future brand acquisitions in the India business to drive growth, but current priority is debt repayment over aggressive investments.
2 more points from Indoco Remedies Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Indoco Remedies Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- As of Q1 FY27, Indoco Remedies Limited has an order book exceeding INR 250 crores for execution.
- The order book mainly comprises exports with longstanding buyer partnerships ensuring consistent push on orders.
- The order book duration is typically between 3 to 6 months, reflecting regular demand cycles and sustained customer relationships.
- There is no fundamental issue with the order book; timing and shipment logistics caused temporary delays, not order shortages.
- The company remains on track to double its export business in 2 to 3 years, including orders for new products.
2 more points from Indoco Remedies Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Indoco Remedies Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹476 Cr, net loss ₹24 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Indoco Remedies Ltd's management said in earlier quarters
- Q2 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Trident Lifeline Ltd (Q1 FY27)
Q1 FY26: ₹23.6 crores . Key investor presentation takeaways from Trident Lifeline Ltd's Q1 FY27 investor presentation — and how it ranks against sector peers.
- Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
- Wanbury Ltd (Q1 FY27)
Q4FY26 Revenue from Operations: ₹164.58 Crore . Key concall takeaways from Wanbury Ltd's Q1 FY27 earnings call — and how it ranks against sector peers.
- Symbiotec Pharma (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹218.2 crores, up 7% YoY from ₹203.2 crores in Q1 FY26 (Page 9). Key concall takeaways from Symbiotec Pharmalab…
Arthneeti Pro · Annual
Indoco Remedies Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Indoco Remedies Ltd Q1 FY27 results?
Overall sales are expected to achieve a 12% to 15% CAGR over the next few years due to investments in product basket and customer growth. Expect a 12%-15% sales CAGR over the next few years driven by investments in product basket and customer growth. - Operating margins are anticipated to consistently improve quarter-on-quarter, supported by better plant efficiencies and cost controls. - India and emerging market businesses are highly profitable and expected to contribute steadily to operating profit growth. - European business profitability is set to improve as manufacturing efficiencies and product mix optimize. - U.S.
What is Indoco Remedies Ltd share price analysis?
Indoco Remedies Ltd currently shows a below-average growth signal. The stock trades at a P/E of N/A with a market cap of ₹2,268 Cr. Investors should review the full earnings analysis for detailed insights.
Is Indoco Remedies Ltd planning capital expenditure?
For FY27, Indoco Remedies expects only maintenance capex, totaling less than INR 40-50 crores for the entire year.
Keep Indoco Remedies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.